Table 3.

Comparison of the cumulative data (current cases and previous reported cases with CVST associated COVID-19) with previously published large-volume studies on CVST without COVID-19

	Cumulative data*	Borhani-Haghighi, et al. [4]	Ferro, et al. [21]	Wasay, et al. [1]	Shakibajahromi, et al. [22]	Borhani-Haghighi, et al. [3]
Date	2020	1993–2010	1998–2001	2009–2012	2012–2016	2000–2007
Number of patients	34	465	624	812	174	568
Ethnicity	Mostly Iranian	Iranian	Mostly European abd American	Asian	Iranian	American
Mean age (years)	49.26	29.5–43.8	39.1	31	37.8	46.9
Female/male ratio	1.42	2.8	2.92	1.43	2.8	1.8
Most common predisposing factors	Idiopathic	gender-related causes (mainly OCP)	Thrombophilia; gender-related causes (mainly OCP)	gender-related causes (pregnancy/puerperium)	gender-related causes (mainly OCP)	Systemic malignancy
Hemorrhagic transformation	55%	11–58%	39.3%	26.7%(MRI), 9.6%(CT)	40.1%	NM
Mortality	35.29%	11.4%	8.3%	3.3% (in hospital)	5.2%	3.5%

CVST cerebral venous sinus thrombosis, COVID-19 coronavirus Disease 2019, OCP oral contraceptive pill, MRI magnetic resonance imaging, CT computed tomography, NM not mentioned

^*Cumulative data (cases with CVST and COVID-19) were obtained from Iran, Singapore, United States, Belgium, Italy, UK, France, Netherlands, and Japan